|Bid||1.3000 x 3000|
|Ask||1.3900 x 3100|
|Day's range||1.2300 - 1.3800|
|52-week range||0.9900 - 2.2300|
|Beta (5Y monthly)||1.08|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
FOSTER CITY, Calif., May 19, 2022--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 327,400 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
FOSTER CITY, Calif., May 17, 2022--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, plans to present a company overview at the H.C. Wainwright Global Investment Conference. The presentation will be available as an on-demand session beginning May 24, 2022 at 7 a.m. ET.
FOSTER CITY, Calif., May 09, 2022--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results for the first quarter of 2022, including current and projected financial resources.